Consensus Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
23.35 ^USD	+2.55%		+21.87%	-16.76%

15/04	Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	MT
12/04	Pharvaris Files Mixed Shelf	MT

Evolution of the average Target Price on Pharvaris N.V.

Price target over the last 5 years

History of analyst recommendation changes

542e33e5c97e267.zuCB470iKSjNlWYTd3oFc9OdrPwYdc3f-l-hP2r9Eck.o6LU0IpWRXeO0hBFEDNRGoPe9rdrPrqOrwjkay2FW7mJjtu8hWtOXoSgUg~31d13a4a186fac36aa31e70fa0acd216

Analyst Recommendations on Pharvaris N.V.

Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	15/04	MT
JMP Securities Raises Pharvaris' Price Target to $49 From $40, Maintains Market Outperform Rating	23/01	MT
Morgan Stanley Raises Price Target on Pharvaris to $35 From $32, Keeps Overweight Rating	07/12	MT
Wedbush Raises Pharvaris' Price Target to $35 From $24, Outperform Rating Kept	07/12	MT
Job losses delight investors	06/12
Morgan Stanley Adjusts Price Target on Pharvaris to $32 From $34, Maintains Overweight Rating	14/11	MT
Wedbush Lowers Pharvaris' PT to $24 From $27, Increases Share Count Assumptions Following Q3 Update, Keeps Outperform Rating Ahead of CHAPTER-1 Data	03/11	MT
Wedbush Initiates Pharvaris at Outperform With $27 Price Target, Sees Opportunity for PHVS416 in the Acute HAE Therapeutic Setting	25/23/25	MT
Wedbush Initiates Pharvaris at Outpeform With $27 Price Target	25/23/25	MT
Morgan Stanley Upgrades Pharvaris to Overweight From Equalweight, Boosts Price Target to $34 From $10	15/23/15	MT
Oppenheimer Raises Pharvaris Price Target to $26 From $24, Maintains Outperform Rating	27/23/27	MT
JMP Securities Adjusts Pharvaris' Price Target to $20 From $23, Keeps Market Outperform Rating	06/23/06	MT
SVB Securities Adjusts Pharvaris' Price Target to $18 From $20, Keeps Outperform Rating	03/23/03	MT
JMP Securities Adjusts Pharvaris' Price Target to $23 From $22, Keeps Market Outperform Rating	11/23/11	MT
JMP Securities Adjusts Price Target on Pharvaris to $22 From $18, Maintains Market Outperform Rating	09/22/09	MT
Oppenheimer Adjusts Pharvaris Price Target to $24 From $22, Maintains Outperform Rating	09/22/09	MT
SVB Securities Adjusts Price Target on Pharvaris to $20 From $25, Keeps Outperform Rating	14/22/14	MT
Oppenheimer Adjusts Pharvaris Price Target to $22 From $48, Maintains Outperform Rating	23/22/23	MT
SVB Securities Adjusts Pharvaris' Price Target to $25 From $45, Maintains Outperform Rating	23/22/23	MT
Morgan Stanley Lowers Pharvaris to Equalweight From Overweight, Price Target to $10 From $40	23/22/23	MT
BofA Securities Downgrades Pharvaris to Underperform From Neutral, Adjusts Price Target to $13 From $26	22/22/22	MT
Wall Street Set for Losses as Rate Hike Fears Resurface Ahead of Jackson Hole	22/22/22	MT
JMP Securities Starts Pharvaris at Market Outperform With $34 Price Target	25/22/25	MT
Morgan Stanley Trims Pharvaris BV's Price Target to $40 From $41, Maintains Overweight Rating	17/22/17	MT
SVB Leerink Adjusts Pharvaris' Price Target to $45 from $50, Keeps Outperform Rating	30/22/30	MT